In a filing, United Therapeutics Corp revealed its PRESIDENT AND COO BENKOWITZ MICHAEL unloaded Company’s shares for reported $3.02 million on Mar 03 ’25. In the deal valued at $311.99 per share,9,679 shares were sold. As a result of this transaction, BENKOWITZ MICHAEL now holds 0 shares worth roughly $0.0.
Then, KURZWEIL RAY sold 15,000 shares, generating $4,755,151 in total proceeds. Upon selling the shares at $317.01, the Director now owns 12,080 shares.
Before that, Thompson Tommy G sold 2,500 shares. United Therapeutics Corp shares valued at $795,838 were divested by the Director at a price of $318.34 per share. As a result of the transaction, Thompson Tommy G now holds 8,480 shares, worth roughly $2.68 million.
Morgan Stanley downgraded its United Therapeutics Corp [UTHR] rating to an Equal-weight from a an Overweight in a research note published on July 11, 2024; the price target was increased to $321 from $310. A number of analysts have revised their coverage, including Goldman’s analysts, who increased its forecast for the stock in mid February from “a Sell” to “a Neutral”. Leerink Partners began covering UTHR with “an Outperform” recommendation on February 05, 2024. Wells Fargo started covering the stock on December 08, 2023. It rated UTHR as “an Overweight”.
Price Performance Review of UTHR
On Friday, United Therapeutics Corp [NASDAQ:UTHR] saw its stock jump 2.67% to $315.91. Over the last five days, the stock has lost -1.29%. United Therapeutics Corp shares have fallen nearly -10.47% since the year began. Nevertheless, the stocks have risen 37.47% over the past one year. While a 52-week high of $417.82 was reached on 02/19/25, a 52-week low of $221.53 was recorded on 03/06/25. SMA at 50 days reached $354.52, while 200 days put it at $343.87.
Levels Of Support And Resistance For UTHR Stock
The 24-hour chart illustrates a support level at 307.74, which if violated will result in even more drops to 299.58. On the upside, there is a resistance level at 322.44. A further resistance level may holdings at 328.98. The Relative Strength Index (RSI) on the 14-day chart is 34.44, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -25.16, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 86.10%. Stochastics %K at 8.18% indicates the stock is a buying.
The most recent change occurred on December 06, 2022 when UBS began covering the stock and recommended ‘”a Buy”‘ rating along with a $320 price target.
